首页> 外文OA文献 >Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

【2h】

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

机译：在日本晚期非小细胞肺癌患者中，帕特鲁单抗新制剂（U3-1287）方法2的第一阶段研究是一种完全人抗HER3单克隆抗体联合厄洛替尼

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer [J] . Shimizu Toshio, Yonesaka Kimio, Hayashi Hidetoshi, Cancer chemotherapy and pharmacology. . 2017,第3期

机译：第1期Patritumab（U3-1287）方法2的新配方研究，一种与日本晚期非小细胞肺癌患者中尔洛替尼结合的全人抗HER3单克隆抗体
2. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer [J] . Nishio Makoto, Horiike Atsushi, Murakami Haruyasu, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第3期

机译：在日本非小细胞肺癌患者中以HER3靶向抗体帕特里单抗（U3-1287）联合厄洛替尼进行I期研究
3. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. [J] . Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：在日本患有晚期实体瘤的患者中，针对HER3的人类单克隆抗体patritumab（U3-1287）的第一阶段和剂量确定研究。
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
6. Phase 1 study of new formulation of patritumab (U3-1287) Process 2 a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer [O] . Toshio Shimizu, Kimio Yonesaka, Hidetoshi Hayashi, -1

机译：在日本晚期非小细胞肺癌患者中帕特鲁单抗新制剂（U3-1287）工艺2的第一阶段研究一种完全人抗HER3单克隆抗体联合厄洛替尼
7. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer [O] . Nishio Makoto, Horiike Atsushi, Murakami Haruyasu, 2015

机译：在日本非小细胞肺癌患者中，HER3靶向抗体帕特里单抗（U3-1287）联合厄洛替尼的I期研究

Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

著录项

相似文献

相关主题

期刊订阅